Compugen Ltd.

Foreign Filer Report • Nov 5, 2019

Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019 false

�������� ��"�	2 380
COMPUGEN LTD
Corporation no: 511779639	10473
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	05/11/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-108223	Time of broadcast: 14:18 14:15:14

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onCompugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

6k_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: TASE	Date of revision of form structure: 29/10/2019
Address: Harokmim 26 , Holon 5885849   , Israel Tel: 03-7658585 , 03-7658525 Fax: 03-7658555
E-mail address: donnag@cgen.com
Previous names of reporting entity:
Name of the Signatory: Krashin Ari Position of Signatory in the reporting corporation: Chief Financial Officer Name of Employer Company:
Address: Pinchas Rosen 72 , Tel Aviv 6951294 Telephone: 054-2244899 Facsimile: 03-7658555 E-mail: arik@cgen.com 1
Israel